Changing Susceptible Body Constitution for COVID-19 Prevention by Chinese Medicine in Hong Kong Residents
NCT04668222 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 480
Last updated 2021-04-28
Summary
Chinese medicine has been used for thousands of years in the treatment of epidemic diseases. Through the long-term struggle with the epidemic, Investigators have accumulated and explored a lot of prevention and control experience. According to recent reports, Chinese medicine plays an important role in the treatment of COVID-19. For example. Therefore, it is of great clinical significance to further develop the prevention of COVID-19 by Chinese medicine. According to the 《Diagnosis and treatment of COVID-19》published by National Health Committee and the experience of professional TCM physician, although the disease is generally susceptible, individuals with the body constitution of "deficiency of Qi and Yang" and "deficiency of Qi and Yin" are more prefer to suffer from COVID-19. Therefore, "Invigorating Qi and Yang, invigorating qi and Yin" can be regarded as the primary strategy of preventing COVID-19. Therefore, "Invigorating Qi and Yang, invigorating qi and Yin" can be regarded as the primary strategy of preventing COVID-19 in Chinese medicine. After a series of questionnaire surveys and blood sample collection, investigators can estimate subjects with body constitution is more likely to infect COVID-19.
Conditions
- COVID19
- Herbal Medicine
Interventions
- DRUG
-
Yu-Ping-Feng formula
Yu-Ping-Feng formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08255). The intake dosage is 5g twice daily.
- DRUG
-
Xiang-Sha-Liu-Jun formula
Xiang-Sha-Liu-Jun formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08252). The intake dosage is 5g twice daily.
- DRUG
-
Liu-Wei-Di-Huang formula
Liu-Wei-Di-Huang formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08273). The intake dosage is 5g twice daily.
- DRUG
-
Placebo for "Deficiency of Qi and Yang"
Placebo for the group of "deficiency of Qi and Yang" is composed of 5% Yu-Ping-Feng formula+Xiang-Sha-Liu-Jun formula
- DRUG
-
Placebo for "Deficiency of Qi and Yin"
Placebo for the group of "deficiency of Qi and Yin" is composed of 5% Yu-Ping-Feng formula+Liu-Wei-Di-Huang formula
Sponsors & Collaborators
-
The University of Hong Kong
lead OTHER
Principal Investigators
-
Yibin Feng, PhD · School of Chinese Medicine, The University of Hong Kong
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-04-30
- Primary Completion
- 2022-11-30
- Completion
- 2022-11-30
Countries
- Hong Kong
Study Locations
More Related Trials
-
Traditional Chinese Medicine for Severe COVID-19
NCT04323332 ·Status: UNKNOWN ·Phase: PHASE3
-
Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19
NCT04380870 ·Status: UNKNOWN
-
REspiratory diSEAse cohoRt Studies of CHinese Medicine for Asthma (RESEARCH- Asthma)
NCT06373692 ·Status: NOT_YET_RECRUITING
-
Survey of Satisfaction on Traditional Chinese Medicine Jing-Guan-Fang (JGF) for COVID-19 Prevention
NCT04388644 ·Status: UNKNOWN
-
Trial of Chinese Herbal Medicine in the Treatment of Upper Respiratory Tract Infections (URTIs)
NCT00887172 ·Status: COMPLETED ·Phase: PHASE4
-
Chinese Medicine for Treating Chronic Pharyngolaryngitis
NCT05665777 ·Status: UNKNOWN ·Phase: PHASE2
-
Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection
NCT04251871 ·Status: UNKNOWN ·Phase: NA
-
Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.
NCT05236309 ·Status: COMPLETED
-
REspiratory diSEAse cohoRt Studies of CHinese Medicine for Pneumonia (RESEARCH-Pneumonia)
NCT06220019 ·Status: NOT_YET_RECRUITING
-
The Use of Chinese Herbal Medicine and Vitamin C by Hospital Care Workers in HK to Prevent COVID-19
NCT05360004 ·Status: UNKNOWN ·Phase: PHASE2
-
Acupuncture and Chinese Herbal Medicine for Long COVID
NCT07285707 ·Status: RECRUITING ·Phase: NA
-
Efficacy of TCM Capsules Lian Hua Qing Wen Jiao Nang in Mild COVID-19 Patients
NCT05275933 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of Traditional Chinese Medicine on Outcomes in Patients With Mild/Moderate Chronic Obstructive Pulmonary Disease
NCT01486186 ·Status: UNKNOWN ·Phase: PHASE2
-
The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection
NCT04664049 ·Status: UNKNOWN
-
The Efficacy and Safety of a Chinese Herbal Medicine for Long COVID Associated Fatigue
NCT05684952 ·Status: UNKNOWN ·Phase: PHASE2
-
RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19
NCT05787327 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluating the Effects of Traditional Chinese Medicine by N-of-1 Trials
NCT03147443 ·Status: UNKNOWN ·Phase: PHASE4
-
The Study of CCTM and Common Diseases
NCT02998944 ·Status: COMPLETED
-
The Preventive Effectiveness of the Individualized Jade Wind-Barrier Herbal Tea Bag on the Common Cold in Elderly With Qi-deficiency Constitution (CCJWBT): A Pragmatic Randomized Controlled Trial
NCT05640570 ·Status: COMPLETED ·Phase: PHASE2
-
Traditional Chinese Medicine for Treatment of Chronic Heart Failure
NCT01939236 ·Status: COMPLETED ·Phase: PHASE2
-
A Pragmatic Randomized Controlled Trial of Chinese Herbal Medicine for Severe Pandemic H1N1 Influenza
NCT01053533 ·Status: UNKNOWN ·Phase: NA
-
Effectiveness of Western Medicine Outpatient Consultations in Primary Care
NCT00887133 ·Status: COMPLETED
-
Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe Pneumonia
NCT03185923 ·Status: UNKNOWN ·Phase: PHASE3
-
Effects of Chinese Medicine on Patients With Severe Acute Exacerbation of COPD
NCT06455670 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19
NCT04278963 ·Status: SUSPENDED ·Phase: PHASE2/PHASE3